Prostate Cancer: Escaping Enzalutamide: Malat1 Contributes to Resistance

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2017 Jun 7

PMID 28585559

Citations 5

Authors

Louise Stone

Affiliations

Soon will be listed here.

Citing Articles

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of functions.

Xu W, Liu L, Cui Z, Li M, Ni J, Huang N Open Med (Wars). 2023; 18(1):20230715.

PMID: 37251536 PMC: 10224628. DOI: 10.1515/med-2023-0715.

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Chen X, Wu Y, Wang X, Xu C, Wang L, Jian J Eur J Med Res. 2022; 27(1):105.

PMID: 35780240 PMC: 9250190. DOI: 10.1186/s40001-022-00730-y.

MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.

Marhold M, Udovica S, Topakian T, Horak P, Horvat R, Tomasich E Cancers (Basel). 2022; 14(3).

PMID: 35159020 PMC: 8833778. DOI: 10.3390/cancers14030749.

LncRNA as a multifunctional regulator in cancer multi-drug resistance.

He J, Zhu S, Liang X, Zhang Q, Luo X, Liu C Mol Biol Rep. 2021; 48(8):1-15.

PMID: 34333735 DOI: 10.1007/s11033-021-06603-7.

The Role of lncRNA Crosstalk in Leading Cancer Metastasis of Head and Neck Squamous Cell Carcinoma.

Wang Y, Wang S, Ren Y, Zhou X Front Oncol. 2020; 10:561833.

PMID: 33123473 PMC: 7566906. DOI: 10.3389/fonc.2020.561833.

References

Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C . Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression. Eur Urol. 2017; 72(5):835-844. PMC: 5802348. DOI: 10.1016/j.eururo.2017.04.005. View